Literature DB >> 29958894

A phylogenetic view of the leukocyte ectonucleotidases.

Enza Ferrero1, Angelo C Faini2, Fabio Malavasi2.   

Abstract

The leukocyte ectonucleotidases are a recently defined family included in the last Human Leukocyte Differentiation Antigens Workshop, giving prominence to these membrane proteins whose catalytic activity is expressed outside the cell. Among the most important substrates of the leukocyte ectonucleotidases are extracellular ATP and NAD+ whose transient increases are not immunologically silent but rather perceived as danger signals by the host. Among the host responses to the release of ATP, NAD+ and related small molecules is their breakdown on behalf of a panel of leukocyte ectonucleotidases - CD38, CD39, CD73, CD157, CD203a and CD203c -, whose activities are concatenated to form two nucleotide-catabolizing channels defined as the canonical and non-canonical adenosinergic pathways. Here, after briefly reviewing the structure and function of the proteins involved in these pathwys, we focus on the genes encoding the ectoenzymes of these adenosinergic pathways. The chromosomal localizations of the enzyme-encoding genes yield a first level of information concerning their origins by duplication and modes of regulation. Further information was obtained from phylogenetic analyses that show ectoenzyme orthologs are conserved in major tetrapod species whereas examination of synteny conservation revealed that the chromosomal regions harboring the ADP-ribosyl cyclases on human chromosome 4 and the ENTPDase CD39 on chromosome 10 show striking similarities in gene content consistent with their being paralogous chromosomal regions derived from a vertebrate whole genome duplication. Thus the connections between some of the leukocyte ectoenzymes run deeper than previously imagined.
Copyright © 2018 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ATP; Comparative genomics; Ectoenzymes; Microsynteny; NAD

Mesh:

Substances:

Year:  2018        PMID: 29958894     DOI: 10.1016/j.imlet.2018.06.008

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  6 in total

Review 1.  The purinergic signalling and inflammation in the pathogenesis and progression of diabetes: key factors and therapeutic targets.

Authors:  André Campos de Lima; Lucas Macedo Chaves; Samantha Nuncio Prestes; Aline Mânica; Andreia Machado Cardoso
Journal:  Inflamm Res       Date:  2022-06-01       Impact factor: 6.986

2.  Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy.

Authors:  Sang-Yong Lee; Vigneshwaran Namasivayam; Nader M Boshta; Arianna Perotti; Salahuddin Mirza; Silvia Bua; Claudiu T Supuran; Christa E Müller
Journal:  RSC Med Chem       Date:  2021-06-16

Review 3.  Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets.

Authors:  Tiziana Vaisitti; Francesca Arruga; Giulia Guerra; Silvia Deaglio
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

Review 4.  Paracrine ADP Ribosyl Cyclase-Mediated Regulation of Biological Processes.

Authors:  Cecilia Astigiano; Andrea Benzi; Maria Elena Laugieri; Francesco Piacente; Laura Sturla; Lucrezia Guida; Santina Bruzzone; Antonio De Flora
Journal:  Cells       Date:  2022-08-24       Impact factor: 7.666

5.  Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity.

Authors:  Alina V Meyer; Diana Klein; Simone de Leve; Klaudia Szymonowicz; Martin Stuschke; Simon C Robson; Verena Jendrossek; Florian Wirsdörfer
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

Review 6.  The Circular Life of Human CD38: From Basic Science to Clinics and Back.

Authors:  Alberto L Horenstein; Angelo C Faini; Fabio Morandi; Cristiano Bracci; Francesco Lanza; Nicola Giuliani; Aneel Paulus; Fabio Malavasi
Journal:  Molecules       Date:  2020-10-21       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.